NF157
| Code | Size | Price |
|---|
| TAR-T16291-5mg | 5mg | £540.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
NF157 significantly decreases the expression of metalloproteinase (MMP)-3, MMP-13, which can be used in the treatment of osteoarthritis (OA). NF157 is a highly selective nanomolar P2Y11 antagonist (pKi: 7.35). The IC50s are 463 nM, 1811 μM, 170 μM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 μM), P2Y2 (Ki=28.9 μM), respectively.
CAS:
104869-26-3
Formula:
C49H28F2N6Na6O23S6
Molecular Weight:
1437.08
Pathway:
Immunology/Inflammation; Neuroscience
Purity:
0.98
SMILES:
Fc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2F)C(=O)Nc2ccc(c3cc(cc(c23)S(=O)(=O)O[Na])S(=O)(=O)O[Na])S(=O)(=O)O[Na])c1)C(=O)Nc1ccc(c2cc(cc(c12)S(=O)(=O)O[Na])S(=O)(=O)O[Na])S(=O)(=O)O[Na]
Target:
COX
References
1. Ullmann H, et al. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem. 2005 Nov 3;48(22):7040-8.
2. Wang D, et al. Inhibition of P2Y11R ameliorated TNF-?-induced degradation of extracellular matrix in human chondrocytic SW1353 cells. Am J Transl Res. 2019 Apr 15;11(4):2108-2116.